

technologický výskum pri skúmaní spoločných biomechanických dráh, najmä v kontexte zápalových markerov a dysregulácie reabsorpcie vápnika, poskytne cenné poznatky, ktoré zrejme posunú naše znalosti v tejto oblasti.

Dôležité sa ukazuje častejšie využívanie nových zobrazovacích postupov a tiež detailnejšie skúmanie patofyziológie MS. Je potrebné pokračovať v identifikácii prekrývajúcich sa biologických ciest, ktoré možno využiť na ďal-

šie pochopenie simultánnej detekcie (aj s pomocou zatiaľ nedostatočných molekulárnych postupov) a zlepšenie manažmentu oboch chorôb, ktoré s veľkou pravdepodobnosťou spolu súvisia viac, ako si myslíme.

LITERATÚRA

- Skolarikos A, Jung H, Neisius A, et al. EAU guidelines on urolithiasis. [Internet]. [cited 2024 July 14]. Available from: <https://uroweb.org/guidelines>.
- Scales C, Smith A, Hanley J, et al. Prevalence of kidney stones in the renal cell carcinoma and upper tract urothelial carcinoma: the Netherlands cohort study. *Br J Cancer*. 2019;120(3):368-374.
- Warli S, Mantiri B, Sihombing B, et al. Nephrolithiasis – associated renal cell carcinoma in patients who underwent nephrectomy: a single center experience. *World J Oncol*. 2023;14(1):94-100.
- Yu Z, Yue W, Jiuzhi L, et al. The risk of bladder cancer in patients with urinary calculi: a meta-analysis. *Urolithiasis*. 2018;46(6):573-579.
- Seggard K, Veres K, Norgaard M, et al. Pyelonephritis in persons after age 50 as a clinical marker of urogenital cancer. *Clin Microbiol Infect*. 2019;25(1):87-91.
- Lin C, Huang W, Fan W, et al. Associations between interventions for urolithiasis and urinary tract cancer among patients in Taiwan. *Medicine*. 2016;95:49:e5594.
- Mihalopoulos M, Yaghoubian A, Razdan S, et al. Understanding the link between kidney stones and cancers of the upper urinary tract and bladder. *Am J Clin Exp Urol*. 2022;10(5):277-298.
- Raghavendran M, Rastogi A, Dubey D, et al. Stones associated renal pelvic malignancies. *Indian J Cancer*. 2003;40(3):108-112.
- Peerapan P, Boonmark W, Putpeerawit P, et al. Calcium oxalate crystals trigger epithelial – mesenchymal transition and carcinogenic features in renal cells: a crossroad between kidney stone disease and renal cancer. *Exp Hematol Oncol*. 2022;11:62.
- Shabani F, Farasat A, Mahdavi M, et al. Calprotectin (S100A8/S100A9): a key protein between inflammation and cancer. *Inflamm Res*. 2018;67(10):801-812.
- Hu H, Chen D, Wang Y, et al. New insights into TGF- β /Smad signaling in tissue fibrosis. *Chem Biol Interact*. 2018;292:76-83.
- Magers M, Kaimakliotis H, Barboza M, et al. Clinicopathological characteristics of pT0N0 urothelial carcinoma following neoadjuvant chemotherapy and cystectomy. *J Clin Pathol*. 2019;72(8):550-553.
- Bayraktar E, Igci M, Erturhan S, et al. Reduced gene expression of bikunin as a prognostic marker for renal cell carcinoma. *Exp Oncol*. 2014;36(2):107-111.
- Blaj V, Li M, Ho S, et al. Design of drug-like hepsin inhibitors against prostate cancer and kidney stones. *Acta Pharm Sin B*. 2020;10(7):1309-1320.
- Lu L, Cole A, Huang D, et al. Clinical significance of hepsin and underlying pathways in prostate cancer. *Biomolecules*. 2022;12(2):203.
- Damalanka V, Han Z, Karmakar P, et al. Discovery of selective matriptase and hepsin serine protease inhibitors: useful chemical tools for cancer and cell biology. *J Med Chem*. 2019;62(2):480-490.
- Schaeffer C, Devuyst O, Rampoldi L. Uromodulin: roles in health and disease. *Annu Rev Physiol*. 2021;83:477-501.
- Michaels E, Grosh L, Nakagawa Y, et al. Immunohistochemical localization of nephrocalcin, a kidney-specific glycoprotein, to renal cell carcinoma. *Urology*. 1988;52(5):920-924.
- Nakagawa Y. Properties and function of nephrocalcin: mechanism of kidney stone inhibition or promotion. *Keio J Med*. 1997;46(1):1-9.
- Nie M, Bal M, Yang Z, et al. Mucin-1 increases renal TRPV5 activity in vitro, and urinary levels associates with calcium nephrolithiasis in patients. *J Am Soc Nephrol*. 2016;27(11):3447-3458.
- Yu L, Andrews N, Zhao Q, et al. Galectin-3 interaction with Thomsen-Friedenreich disaccharide on cancer-associated MUC1 causes increased cancer cell endothelial adhesion. *J Biol Chem*. 2007;282(1):773-781.
- Mao W, Wang K, Wu Z, et al. Current status of research on exosomes in general, and for the diagnosis and treatment of kidney cancer in particular. *J Exp Clin Cancer Res*. 2021;40(1):305.
- Wang L, Yang G, Zhao D, et al. CD103-positive CSC exosome promotes EMT of clear cell renal cell carcinoma: role of remote Mir-19b-3p. *Mol Cancer*. 2019;18(1):86.
- Singh N, Kanlaya R, Nilnumkhum A, et al. Roles of macrophage exosomes in immune response to calcium oxalate monohydrate crystals. *Fron Immunol*. 2018;9:316.
- Wang Q, Sun Y, Yang Y, et al. Quantitative proteomic analysis of urinary exosomes in kidney stones patients. *Transl Androl Urol*. 2020;9(4):1572-1584.
- Hemminki K, Hemminki O, Försti A, et al. Familial risks between urolithiasis and cancer. *Sci Rep*. 2018;8(1):3083.
- Goldfarb D, Avery A, Beara-Lasic R, et al. A twin study of genetic influences on nephrolithiasis in women and men. *Kidney Int Rep*. 2018;4(4):535-540.
- Hemminki K, Hemminki O, Försti A, et al. Familial risks in urolithiasis in the population of Sweden. *BJU Int*. 2018;121(3):479-485.
- Howles S, Thakker R. Genetics of kidney stone disease. *Nat Rev Urol*. 2020;17(7):407-421.
- Sadeghi-Bojd S, Falsafinejad F, Danesh H, et al. Macrophage migration inhibitory factor-173 G>C gene polymorphism is associated with increased risk of nephrotic syndrome in children. *Iran J Kidney Dis*. 2019;13:232-236.
- Ma G, Yuan Q, Wang Q, et al. Association between MIF-AS rs755622 and nephrolithiasis risk in Chinese population. *Med Sci Monit*. 2016;22:563-568.
- Sun X, Kour B, Wang X, et al. Insights into association between urolithiasis and prostate cancer. *J Mens Health*. 2021;17(4):52-61.
- Tang K, Liu H, Jiang K, et al. Predictive value of preoperative inflammatory response biomarkers for metabolic syndrome and post-PCNL systemic inflammatory response syndrome in patients with nephrolithiasis. *Oncotarget*. 2017;8(49):85612-85627.
- Spatola L, Ferraro P, Garbaro G, et al. Metabolic syndrome and uric acid nephrolithiasis: insulin resistance in focus. *Metabolism*. 2018;83:225-233.
- Uzunlulu M, Telci Kaklili O, Oguz A. Association between metabolic syndrome and cancer. *Ann Nutr Metab*. 2016;68(3):173-179.
- Lifshitz K, Ber Y, Margel D. Role of metabolic syndrome in prostate cancer development. *Eur Urol Focus*. 2021;7:508-512.
- Wang F, Xu Y. Body mass index and risk of renal cancer: a dose-response meta-analysis of published cohort studies. *Int J Cancer*. 2014;135(7):1673-1686.
- Song X, Fan B, Ma C, et al. Clinical research on the correlations between type 2 diabetes mellitus and renal clear cell carcinoma. *Zhonghua Wai Ke Za Zhi*. 2013;51(7):627-630.
- Borghini L, Meschi T, Guerra A, et al. Essential arterial hypertension and stone disease. *Kidney Int*. 1999;55(6):2397-2406.
- Cupisti A, D'Alessandro C, Samoni S, et al. Nephrolithiasis and hypertension: possible links and clinical implications. *J Nephrol*. 2014;27(5):477-482.
- Kim C, Han K, Choi H, et al. Association of hypertension and blood pressure with kidney cancer risk: a nationwide population-based cohort study. *Hypertension*. 2020;75(6):1439-1446.
- Hidayat K, Du X, Zou S, et al. Blood pressure and kidney cancer risk: meta-analysis of prospective studies. *J Hypertens*. 2017;35(7):1333-1344.
- Setiawan Y, Stram D, Nomura A, et al. Risk factors for renal cell cancer: the multiethnic cohort. *Am J Epidemiol*. 2007;166(8):932-940.
- Liu C, Huang S, Wu W, et al. The impact of cigarette smoking, alcohol drinking and betel quid chewing on the risk of calcium urolithiasis. *Ann Epidemiol*. 2009;19(8):539-545.
- Soueidan M, Bartlett S, Noureldin Y, et al. Leisure time physical activity, smoking and risk of recent symptomatic urolithiasis: survey of stone clinic patients. *Can Urol Assoc J*. 2015;9(7-8):257-262.
- Sun Y, Zhou Q, Zheng J. Nephrotoxic metals of cadmium, lead, mercury and arsenic and the odds of kidney stones in adults: an exposure-response analysis of NHANES 2007–2016. *Environ Int*. 2019;132:105115.
- Jones P, Karim Sulaiman S, Gamage K, et al. Do lifestyle factors including smoking, alcohol, and exercise impact your risk of developing kidney stone disease? Outcomes of a systematic review. *J Endourol*. 2021;35(1):1-7.
- World Cancer Research Fund International/American Institute for Cancer Research. Continuous Update Project Report. Diet, Nutrition, Physical Activity and Kidney Cancer. 2015. [Internet]. Available at: wcrf.org/kidney-cancer-2015.
- Zhu Y, Horikawa Y, Yang H, et al. BPDE induced lymphocytic chromosome 3p deletions may predict renal cell carcinoma risk. *J Urol*. 2008;179(6):2416-2421.
- Lee J, Hunter D, Spiegelman D, et al. Alcohol intake and renal cell cancer in a pooled analysis of 12 prospective studies. *J Natl Cancer Inst*. 2007;99(10):801-810.
- Wang H, Fan J, Yu C, et al. Consumption of tea, alcohol and fruits and risk of kidney stones: a prospective cohort study in 0.5 million Chinese adults. *Nutrients*. 2021;13(4):1119.
- Zaitsum M, Kawachi I, Takeuchi T, et al. Alcohol consumption and risk of upper-tract urothelial cancer. *Cancer Epidemiol*. 2017;48:36-40.
- Witjes J, Bruins H, Carrión A, et al. EAU guidelines on muscle invasive and metastatic bladder cancer. [Internet]. [cited 2024 July 14]. Available from: <https://uroweb.org/guidelines>.
- Thongboonkiet V. Roles for exosome in various kidney diseases and disorders. *Fron Pharmacol*. 2020;10:1655.
- Kim M, Hopfer H, Mayr M. Uric acid, kidney disease and nephrolithiasis. *Ther Umsch*. 2016;73(3):159-165.